PMID- 31630144
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20200928
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 236
IP  - 1
DP  - 2020
TI  - Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne 
      Inversa.
PG  - 25-30
LID - 10.1159/000503606 [doi]
AB  - BACKGROUND: Adalimumab is the only approved compound for the treatment of adult 
      patients with moderate-to-severe hidradenitis suppurativa (HS) who did not 
      respond to a systemic classical treatment. Despite its significant short- and 
      long-term efficacy, a percentage of patients do not respond sufficiently. 
      Moreover, some primary responders experience a response loss with time. 
      OBJECTIVE: To analyse the effectiveness of adalimumab dose intensification in HS 
      patients. METHODS: A case series of adalimumab 80 mg/week subcutaneously (s.c.) 
      compassionate use in patients with HS, who did not respond sufficiently or in 
      primary responders with progressive response loss to the registered adalimumab 
      dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. 
      Patients' data were extracted from medical records. RESULTS: The 14 patients 
      collected were Caucasian with HS of Hurley stage II-III and moderate or severe 
      International HS Severity Score System (IHS4) stage. Adalimumab dose 
      intensification significantly improved IHS4 score, Pain Index, HS-Physician 
      Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young 
      female patients with HS and Crohn's disease developed psoriatic lesions during 
      the treatment with adalimumab 80 mg/week s.c. CONCLUSION: An enhanced level of 
      effectiveness was assessed in the majority of the HS patients treated with 
      adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to 
      evaluate this observation.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Zouboulis, Christos C
AU  - Zouboulis CC
AD  - Departments of Dermatology, Venereology, Allergology and Immunology, Dessau 
      Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany, 
      christos.zouboulis@mhb-fontane.de.
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany, 
      christos.zouboulis@mhb-fontane.de.
FAU - Hansen, Hendrik
AU  - Hansen H
AD  - Departments of Dermatology, Venereology, Allergology and Immunology, Dessau 
      Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
FAU - Caposiena Caro, Raffaele Dante
AU  - Caposiena Caro RD
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
AD  - Department of Dermatology, Department of Systems Medicine, University of Rome Tor 
      Vergata, Rome, Italy.
FAU - Damiani, Giovanni
AU  - Damiani G
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
AD  - Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
FAU - Delorme, Isabelle
AU  - Delorme I
AD  - Dr. Isabelle Delorme Inc., Drummondville, Quebec, Canada.
FAU - Pascual, Jose Carlos
AU  - Pascual JC
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
AD  - Department of Dermatology, Alicante University General Hospital, Alicante 
      Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), 
      Alicante, Spain.
FAU - Reguiai, Ziad
AU  - Reguiai Z
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
AD  - Department of Dermatology, Reims University Hospital, University of 
      Champagne-Ardenne, Reims, France.
FAU - Trigoni, Anastasia
AU  - Trigoni A
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
AD  - Second Department of Dermatology and Venereology, General Hospital Papageorgiou, 
      Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Vilarrasa, Eva
AU  - Vilarrasa E
AD  - European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
AD  - Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Alfageme Roldan, Fernando
AU  - Alfageme Roldan F
AD  - Department of Dermatology, University Hospital Puerta De Hierro Majadahonda, 
      Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20191018
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Dermatologic Agents)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/*administration & dosage
MH  - Adult
MH  - Dermatologic Agents/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hidradenitis Suppurativa/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Young Adult
OTO - NOTNLM
OT  - Acne inversa
OT  - Adalimumab
OT  - Hidradenitis suppurativa
OT  - Intensification
OT  - Treatment
EDAT- 2019/10/21 06:00
MHDA- 2020/09/29 06:00
CRDT- 2019/10/21 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2019/09/23 00:00 [accepted]
PHST- 2019/10/21 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2019/10/21 06:00 [entrez]
AID - 000503606 [pii]
AID - 10.1159/000503606 [doi]
PST - ppublish
SO  - Dermatology. 2020;236(1):25-30. doi: 10.1159/000503606. Epub 2019 Oct 18.